List of Excipients in API TAFAMIDIS MEGLUMINE
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing TAFAMIDIS MEGLUMINE
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | VYNDAQEL | tafamidis meglumine | 0069-1975 | AMMONIA | 2035-08-31 |
| Pfizer Laboratories Div Pfizer Inc | VYNDAQEL | tafamidis meglumine | 0069-1975 | FD&C BLUE NO. 1 | 2035-08-31 |
| Pfizer Laboratories Div Pfizer Inc | VYNDAQEL | tafamidis meglumine | 0069-1975 | FERRIC OXIDE YELLOW | 2035-08-31 |
| Pfizer Laboratories Div Pfizer Inc | VYNDAQEL | tafamidis meglumine | 0069-1975 | GELATIN | 2035-08-31 |
| Pfizer Laboratories Div Pfizer Inc | VYNDAQEL | tafamidis meglumine | 0069-1975 | GLYCERIN | 2035-08-31 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for TAFAMIDIS MEGLUMINE
Excipient focus: AMMONIA
TAFAMIDIS MEGLUMINE drug variants containing AMMONIA
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tafamidis meglumine | 0069-1975 |
| >Company | >Ingredient | >NDC |
TAFAMIDIS MEGLUMINE drug variants not containing AMMONIA
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 1
TAFAMIDIS MEGLUMINE drug variants containing FD&C BLUE NO. 1
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tafamidis meglumine | 0069-1975 |
| >Company | >Ingredient | >NDC |
TAFAMIDIS MEGLUMINE drug variants not containing FD&C BLUE NO. 1
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
TAFAMIDIS MEGLUMINE drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tafamidis meglumine | 0069-1975 |
| >Company | >Ingredient | >NDC |
TAFAMIDIS MEGLUMINE drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: GELATIN
TAFAMIDIS MEGLUMINE drug variants containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tafamidis meglumine | 0069-1975 |
| >Company | >Ingredient | >NDC |
TAFAMIDIS MEGLUMINE drug variants not containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCERIN
TAFAMIDIS MEGLUMINE drug variants containing GLYCERIN
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tafamidis meglumine | 0069-1975 |
| >Company | >Ingredient | >NDC |
TAFAMIDIS MEGLUMINE drug variants not containing GLYCERIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PIGMENT RED 48
TAFAMIDIS MEGLUMINE drug variants containing PIGMENT RED 48
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tafamidis meglumine | 0069-1975 |
| >Company | >Ingredient | >NDC |
TAFAMIDIS MEGLUMINE drug variants not containing PIGMENT RED 48
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 400
TAFAMIDIS MEGLUMINE drug variants containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tafamidis meglumine | 0069-1975 |
| >Company | >Ingredient | >NDC |
TAFAMIDIS MEGLUMINE drug variants not containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 80
TAFAMIDIS MEGLUMINE drug variants containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tafamidis meglumine | 0069-1975 |
| >Company | >Ingredient | >NDC |
TAFAMIDIS MEGLUMINE drug variants not containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ACETATE PHTHALATE
TAFAMIDIS MEGLUMINE drug variants containing POLYVINYL ACETATE PHTHALATE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tafamidis meglumine | 0069-1975 |
| >Company | >Ingredient | >NDC |
TAFAMIDIS MEGLUMINE drug variants not containing POLYVINYL ACETATE PHTHALATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
TAFAMIDIS MEGLUMINE drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tafamidis meglumine | 0069-1975 |
| >Company | >Ingredient | >NDC |
TAFAMIDIS MEGLUMINE drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SORBITAN MONOOLEATE
TAFAMIDIS MEGLUMINE drug variants containing SORBITAN MONOOLEATE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tafamidis meglumine | 0069-1975 |
| >Company | >Ingredient | >NDC |
TAFAMIDIS MEGLUMINE drug variants not containing SORBITAN MONOOLEATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SORBITOL
TAFAMIDIS MEGLUMINE drug variants containing SORBITOL
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tafamidis meglumine | 0069-1975 |
| >Company | >Ingredient | >NDC |
TAFAMIDIS MEGLUMINE drug variants not containing SORBITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
TAFAMIDIS MEGLUMINE drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tafamidis meglumine | 0069-1975 |
| >Company | >Ingredient | >NDC |
TAFAMIDIS MEGLUMINE drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
